Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Lei Chen"'
Autor:
William M. Reichmann, Eric Q. Wu, Darren Thomason, Keith A. Betts, Daniel J. DeAngelo, James Signorovitch, Phil Galebach, Lei Chen
Publikováno v:
Current Medical Research and Opinion. 31:315-322
Nilotinib and dasatinib have shown superior rates of molecular response (MR) compared to imatinib for the treatment of newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CP). This study indirectly compares MR in patients taking nilotini
Publikováno v:
Journal of Medical Economics. 17:89-98
Molecular monitoring of chronic myeloid leukemia (CML) has been associated with improved clinical outcomes during tyrosine kinase inhibitor therapy (TKI), yet recent studies have demonstrated its use is far below published guidelines. This study soug
Autor:
Mansoor N. Saleh, Lei Chen, Kavita R. Sail, Sally Haislip, Tamara Hess, James H. Jackson, Solveig G. Ericson, James Gilmore, Joyce Sharpe
Publikováno v:
Current Medical Research and Opinion. 30:529-536
Real-world treatment and monitoring patterns have not been well documented among imatinib-treated chronic phase chronic myeloid leukemia (CP-CML) patients. Thus, we evaluated these patterns and responses to imatinib in CP-CML patients.This retrospect
Publikováno v:
Expert Opinion on Therapeutic Targets. 17:1115-1118
Objectives: This study aimed to explore why one acute promyelocytic leukemia (APL) patient underwent complete molecular remission in the persistent presence of the t (2; 3) (p25; q21) karotype. Methods: One APL patient overexpressed PML/RARα (bcr1)
Autor:
Solveig G. Ericson, Eric Q. Wu, Jipan Xie, Elias Jabbour, Lei Chen, Annie Guerin, Andrew P. Yu
Publikováno v:
Current Medical Research and Opinion. 28:1831-1839
Monitoring treatment response is an integral part of chronic myeloid leukemia (CML) treatment. The guidelines recommend regular monitoring using standard methods (e.g., real-time quantitative polymerase chain reaction based on the international scale
Publikováno v:
Current Medical Research and Opinion. 28:1155-1162
To compare adherence to second-generation tyrosine kinase inhibitors (TKIs) dasatinib and nilotinib in patients with imatinib resistant or intolerant chronic myeloid leukemia (CML) receiving second-line therapies.Two U.S. administrative claims databa
Autor:
David Laitinen, Anna Kaltenboeck, Shiraz R. Gupta, Steve Feldman, Eric Q. Wu, Mary K. Willian, Andrew P. Yu, Lei Chen
Publikováno v:
Current Medical Research and Opinion. 24:3493-3501
To describe the utilization patterns, particularly dosage-escalation patterns, and economic implications of etanercept in the treatment of moderate to severe psoriasis in a real-world setting.Patients with psoriasis receiving etanercept were identifi
Publikováno v:
Current Medical Research and Opinion. 24:2229-2240
To describe dosing patterns for tumor necrosis factor (TNF) antagonists in patients with rheumatoid arthritis from health care provider and payer point of interest.Using privately insured US claims data from 31 large employers covering 31 companies a
Publikováno v:
Current Medical Research and Opinion. 23:1749-1759
To compare the cost of care for rheumatoid arthritis (RA) patients treated with adalimumab, infliximab, and etanercept.RA patients were identified from a privately insured database. Three mutually exclusive treatment cohorts were formed based on the
Autor:
Lei Chen, Eric Q. Wu
Publikováno v:
Current Medical Research and Opinion. 28:1163-1165